CY1121654T1 - Διαδερματικα συστηματα αποτρεπτικα καταχρησης και εσφαλμενης χρησης - Google Patents
Διαδερματικα συστηματα αποτρεπτικα καταχρησης και εσφαλμενης χρησηςInfo
- Publication number
- CY1121654T1 CY1121654T1 CY20191100558T CY191100558T CY1121654T1 CY 1121654 T1 CY1121654 T1 CY 1121654T1 CY 20191100558 T CY20191100558 T CY 20191100558T CY 191100558 T CY191100558 T CY 191100558T CY 1121654 T1 CY1121654 T1 CY 1121654T1
- Authority
- CY
- Cyprus
- Prior art keywords
- deterrent
- abuse
- misuse
- patch
- sustained release
- Prior art date
Links
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000002940 repellent Effects 0.000 abstract 2
- 239000005871 repellent Substances 0.000 abstract 2
- 238000013268 sustained release Methods 0.000 abstract 2
- 239000012730 sustained-release form Substances 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 230000002051 biphasic effect Effects 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 229940127240 opiate Drugs 0.000 abstract 1
- 239000000014 opioid analgesic Substances 0.000 abstract 1
- 229940005483 opioid analgesics Drugs 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000021 stimulant Substances 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 230000037317 transdermal delivery Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F214/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen
- C08F214/18—Monomers containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F214/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a halogen
- C08F214/18—Monomers containing fluorine
- C08F214/26—Tetrafluoroethene
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Materials Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Αποτρεπτικό κατάχρησης και αποτρεπτικό εσφαλμένης χρήσης διαδερματικό αυτοκόλλητο που περιλαμβάνει απωθητικούς παράγοντες που ενσωματώνονται στην στοιβάδα υποστήριξης του αυτοκόλλητου. Οι απωθητικοί παράγοντες μπορούν να δεικνύουν διφασικές ή παρατεταμένες κινητικές απελευθέρωσης με άμεσο τμήμα απελευθερούμενο ταχέως και εκτεταμένο τμήμα απελευθερούμενο με παρατεταμένο τρόπο όταν εκτίθεται σε μέσο διαλυτοποίησης. Ο παρατεταμένος απωθητικός παράγων απελευθέρωσης παρέχει αποθάρρυνση έναντι εξαγωγής του φαρμάκου από νέα και χρησιμοποιημένα αυτοκόλλητα και χρησιμεύει στην αποτροπή τυχαίας εσφαλμένης χρήσης χρησιμοποιημένων αυτοκόλλητων από τα παιδιά. Τα συστήματα αποτρεπτικού κατάχρησης και αποτρεπτικού εσφαλμένης χρήσης αυτοκόλλητου μπορεί να χρησιμοποιηθούν για διαδερματική απελευθέρωση θεραπευτικώς δραστικών παραγόντων και ιδιαιτέρως αυτών των φαρμάκων που είναι ιδιαιτέρως επιρρεπή σε κατάχρηση όπως οπιούχων και οπιοειδών αναλγητικών και διεγερτικών.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461930090P | 2014-01-22 | 2014-01-22 | |
US201461930104P | 2014-01-22 | 2014-01-22 | |
US201462014723P | 2014-06-20 | 2014-06-20 | |
US201462014721P | 2014-06-20 | 2014-06-20 | |
US201462083620P | 2014-11-24 | 2014-11-24 | |
PCT/US2015/012196 WO2015112563A2 (en) | 2014-01-22 | 2015-01-21 | Abuse and misuse deterrent transdermal systems |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121654T1 true CY1121654T1 (el) | 2020-07-31 |
Family
ID=53682116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20191100558T CY1121654T1 (el) | 2014-01-22 | 2019-05-24 | Διαδερματικα συστηματα αποτρεπτικα καταχρησης και εσφαλμενης χρησης |
Country Status (20)
Country | Link |
---|---|
US (5) | US20170007550A1 (el) |
EP (1) | EP3096746B1 (el) |
JP (1) | JP6525165B2 (el) |
KR (1) | KR102226652B1 (el) |
CN (3) | CN106459293A (el) |
AU (1) | AU2015209466B2 (el) |
CA (1) | CA2937649C (el) |
CY (1) | CY1121654T1 (el) |
DK (1) | DK3096746T3 (el) |
ES (1) | ES2729871T3 (el) |
HR (1) | HRP20191048T1 (el) |
HU (1) | HUE044966T2 (el) |
LT (1) | LT3096746T (el) |
MX (1) | MX369030B (el) |
PL (1) | PL3096746T3 (el) |
PT (1) | PT3096746T (el) |
RS (1) | RS58759B1 (el) |
RU (1) | RU2700926C2 (el) |
SI (1) | SI3096746T1 (el) |
WO (1) | WO2015112563A2 (el) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2729871T3 (es) * | 2014-01-22 | 2019-11-06 | 4P Therapeutics | Sistemas transdérmicos disuasivos del abuso y del mal uso |
JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. | 薬剤送達方法及びシステム |
EP3267875A4 (en) | 2015-03-12 | 2018-12-05 | Chrono Therapeutics Inc. | Craving input and support system |
US20170273974A1 (en) | 2016-03-24 | 2017-09-28 | Medrx Co., Ltd | Patch preparations with misuse prevention features |
JPWO2017164084A1 (ja) * | 2016-03-24 | 2019-02-07 | 株式会社 メドレックス | 誤用防止特性を有する貼付製剤 |
EP3565617A1 (en) | 2017-01-06 | 2019-11-13 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
AU2019279884A1 (en) | 2018-05-29 | 2020-12-10 | Morningside Venture Investments Limited | Drug delivery methods and systems |
JP2021535206A (ja) * | 2018-08-23 | 2021-12-16 | バーンスタイン,エリック,エフ. | 皮膚状態を治療するために抗vegf化合物を適用するためおよびこのような化合物を使用するためのシステム、デバイスおよび方法 |
CN112526037A (zh) * | 2020-12-07 | 2021-03-19 | 温州市质量技术检测科学研究院 | 一种检测巴克球中苦精的方法 |
CN114668748A (zh) * | 2022-05-18 | 2022-06-28 | 张钊源 | 渐变型透皮贴剂及其制备方法、药物方面的应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990026792A (ko) * | 1997-09-26 | 1999-04-15 | 김윤 | 디클로페낙 디에틸암모늄염을 함유한 매트릭스형 패취제제 |
GB0026137D0 (en) * | 2000-10-25 | 2000-12-13 | Euro Celtique Sa | Transdermal dosage form |
WO2003090729A1 (en) * | 2002-04-23 | 2003-11-06 | Alza Corporation | Transdermal analgesic systems with reduced abuse potential |
PT1530469E (pt) * | 2002-08-20 | 2009-05-19 | Euro Celtique Sa | Forma de dosagem transdérmica que compreende um agente activo, um sal e uma forma de base livre de um antagonista |
US20040109886A1 (en) * | 2002-08-27 | 2004-06-10 | Larry Rigby | Methods and apparatus for transdermal delivery of abusable drugs with a deterrent agent |
KR20060002927A (ko) * | 2003-04-04 | 2006-01-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 가스 흐름으로부터 이산화탄소를 제거하기 위한폴리아민/알칼리 염 혼합물 |
EA009623B1 (ru) * | 2003-04-30 | 2008-02-28 | Пэдью Фарма Л.П. | Устойчивая к манипуляциям дозировочная форма для трансдермального введения |
US20040219195A1 (en) * | 2003-04-30 | 2004-11-04 | 3M Innovative Properties Company | Abuse-resistant transdermal dosage form |
CN1780611B (zh) * | 2003-04-30 | 2013-01-30 | 珀杜医药公司 | 包括活性剂部分以及在活性剂层远侧的逆转剂的抗改造透皮剂型 |
US20080020028A1 (en) * | 2003-08-20 | 2008-01-24 | Euro-Celtique S.A. | Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent |
AU2004286852A1 (en) * | 2003-10-30 | 2005-05-19 | Alza Corporation | Transdermal analgesic systems having reduced abuse potential |
ME02661B (me) * | 2004-02-23 | 2017-06-20 | Euro Celtique Sa | Opioidni transdermalni preparat otporan na zloupotrebu |
JP5213204B2 (ja) * | 2004-03-08 | 2013-06-19 | リンテック株式会社 | 粘着シートおよびその製造方法 |
KR100663163B1 (ko) * | 2005-10-24 | 2007-01-02 | (주)아모레퍼시픽 | 비스테로이드성 소염진통제를 함유하는 경피 투여 제제 |
WO2008024408A2 (en) * | 2006-08-22 | 2008-02-28 | Theraquest Biosciences, Inc. | Pharmaceutical formulations of cannabinoids for application to the skin and method of use |
WO2008133982A2 (en) * | 2007-04-27 | 2008-11-06 | Lectec Corporation | Adhesive patch with aversive agent |
EP2299989B1 (en) * | 2008-05-30 | 2019-01-02 | Mylan Inc. | Stabilized transdermal drug delivery system |
WO2011085406A1 (en) * | 2010-01-11 | 2011-07-14 | Mithridion, Inc. | Compounds and compositions for cognition-enhancement, methods of making, and methods of treating |
US20110293681A1 (en) * | 2010-02-26 | 2011-12-01 | Lectec Corporation | Hand sanitizing patch having an integrally bonded antimicrobial |
EP2552425B1 (en) * | 2010-04-02 | 2016-07-27 | Buzzz Pharmaceuticals Limited | Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists |
ES2729871T3 (es) * | 2014-01-22 | 2019-11-06 | 4P Therapeutics | Sistemas transdérmicos disuasivos del abuso y del mal uso |
CN112741822A (zh) * | 2019-10-30 | 2021-05-04 | 江苏集萃新型药物制剂技术研究所有限公司 | 一种用于皮肤或粘膜释放活性物质的透皮贴剂给药系统 |
-
2015
- 2015-01-21 ES ES15740893T patent/ES2729871T3/es active Active
- 2015-01-21 EP EP15740893.1A patent/EP3096746B1/en active Active
- 2015-01-21 CN CN201580015604.6A patent/CN106459293A/zh active Pending
- 2015-01-21 US US15/113,545 patent/US20170007550A1/en not_active Abandoned
- 2015-01-21 CA CA2937649A patent/CA2937649C/en active Active
- 2015-01-21 RS RS20190637A patent/RS58759B1/sr unknown
- 2015-01-21 LT LTEP15740893.1T patent/LT3096746T/lt unknown
- 2015-01-21 HU HUE15740893 patent/HUE044966T2/hu unknown
- 2015-01-21 PT PT15740893T patent/PT3096746T/pt unknown
- 2015-01-21 RU RU2016133853A patent/RU2700926C2/ru active
- 2015-01-21 DK DK15740893.1T patent/DK3096746T3/da active
- 2015-01-21 MX MX2016009493A patent/MX369030B/es active IP Right Grant
- 2015-01-21 AU AU2015209466A patent/AU2015209466B2/en active Active
- 2015-01-21 PL PL15740893T patent/PL3096746T3/pl unknown
- 2015-01-21 WO PCT/US2015/012196 patent/WO2015112563A2/en active Application Filing
- 2015-01-21 KR KR1020167022446A patent/KR102226652B1/ko active IP Right Grant
- 2015-01-21 CN CN202211157116.7A patent/CN115444659A/zh active Pending
- 2015-01-21 CN CN202211158031.0A patent/CN115475048A/zh active Pending
- 2015-01-21 SI SI201530710T patent/SI3096746T1/sl unknown
- 2015-01-21 JP JP2016548240A patent/JP6525165B2/ja active Active
-
2018
- 2018-11-14 US US16/190,749 patent/US20190076374A1/en not_active Abandoned
-
2019
- 2019-05-24 CY CY20191100558T patent/CY1121654T1/el unknown
- 2019-06-11 HR HRP20191048TT patent/HRP20191048T1/hr unknown
- 2019-12-09 US US16/707,547 patent/US11246840B2/en active Active
-
2022
- 2022-01-05 US US17/568,999 patent/US11759431B2/en active Active
-
2023
- 2023-09-18 US US18/369,241 patent/US20240000720A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121654T1 (el) | Διαδερματικα συστηματα αποτρεπτικα καταχρησης και εσφαλμενης χρησης | |
CY1123571T1 (el) | Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα | |
CO2017006828A2 (es) | Composiciones fungicidas | |
CY1120389T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει εναν glp-1-αγωνιστη, μια ινσουλινη και μεθειονινη | |
NI201800038S (es) | Dispositivo de administración de medicamento intranasal | |
CY1121563T1 (el) | Συστημα απελευθερωσης φαρμακου για χρηση στην αντισυλληψη που περιλαμβανει πυρηνα και μια θηκη | |
NZ758050A (en) | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics | |
CL2014003444A1 (es) | Compuestos derivados tienopirimidina; proceso de preparacion; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de canceres y enfermedades autoinmunes. | |
MX2016011744A (es) | Soluciones de buprenorfina de liberacion sostenida. | |
CL2015000345A1 (es) | Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib. | |
CY1119254T1 (el) | Μαρκες ασφαλειας | |
EA201690967A1 (ru) | Глазное устройство | |
CO2017005010A2 (es) | Sistema de entrega nano particulado | |
MX2018001511A (es) | Polimeros furtivos desordenados de forma intrinseca codificados geneticamente para suministro y metodos para usar los mismos. | |
MX2017003623A (es) | Parche de opipramol. | |
ECSP17044282A (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
CL2013001009A1 (es) | Compuestos heterociclicos fusionados; composicion farmaceutica que los comprende, y uso en el tratamiento de un trastorno proliferativo tal como cancer. | |
DK3706841T3 (da) | Kanyleskjoldsfjerner og medikamentafgivelsesindretning, der omfatter kanyleskjoldsfjerneren | |
CL2017000664A1 (es) | Micropartículas inyectables para la liberación hiper-localizada de agentes terapéuticos | |
IL262728A (en) | Oligonucleotides conjugated to the ligand complex of the glp-1 receptor and their uses | |
CL2014003525A1 (es) | Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension. | |
BR112016009749A8 (pt) | hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide | |
BR112017006918A2 (pt) | formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares | |
UY35838A (es) | Sistema de localización y destrucción de armas | |
Balhara | A curious case of the World Health Organization's (WHO) approach on alcohol use disorders--inferences from the WHO list of essential drugs |